Neurotransmitter transporter SC6

Details Neurotransmitter transporter SC6 Neurotransmitter transporter SC6

2001-02-28

2002-07-30

Kermmerer, Elizabeth C. (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S351000

Reexamination Certificate

active

06426405

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and /or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing and the various tools of bioformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
In the central and peripheral nervous system, reliable neurotransmission depends on rapid termination of transmitter action following postsynaptic activation. In some cases this is achieved by metabolism of the neurotransmitter, as in the case of acetycholine and neuropeptides. In many cases, however, including catecholamines, serotonin and some amino acids (e.g. GABA, glycine and glutamate), the neurotransmitter is efficiently removed into the presynaptic terminal or surrounding glial cells by neurotransmitter transporters, membrane-bound polypeptides located in the plasma membrane.
Recently, cDNAs encoding a number of Na/Cl-dependent neurotransmitter transporters (e.g. for serotonin, catecholamine, amino acid (glycine, GABA)) have been described. The general structure of this class of transporter is very similar, containing twelve potential transmembrane helices and an external loop with 3-4 glycosylation sites between transmembrane segments 3 and 4. In GABA and catecholamine transporter subfamilies, the amino acid sequence is about 60-80% identical to other members within a subfamily and about 40% identical to members between two subfamilies (Liu et al., Proc. Natl. Acad. Sci. USA, (1992), 89:6639-6643). Transporters of amino acids such as glycine share about 40-50% homology with all members of the neurotransmitter transporter superfamily. Two classes of glycine transporter, GlyT-1 and GlyT-2, have been identified (Liu et al, J. Biol. Chem. (1992),268, 22802-22808). Rat GlyT-2 has about 50% amino acid sequence identity with either human or rat GlyT-1.
Glycine is a major transmitter in the nervous system. Glycine can have both inhibitory and excitatory functions, which are mediated by two different types of receptor, each associated with a different class of glycine transporter. The excitatory function of glycine is mediated by “strychnine-insensitive” glycine receptors, which are part of the NMDA receptor complex which mediates some of the actions of glutamate, the major excitatory transmitter in the central nervous system. This type of glycine receptor is widely distributed throughout the brain, and is associated with the GlyT-1 transporter. Conversly, the inhibitory action of glycine is mediated by “strychnine-sensitive” glycine receptors. These receptors are found mainly in the spinal cord, brainstem and cerebellum, and are associated with the GlyT-2 transporter.
Modulation of neurotransmitter transport enables synaptic transmission to be increased or decreased by altering the levels of neurotransmitter in the synaptic cleft, and blockade of transport is an established approach to the treatment of psychiatric and neurological illness. Drugs which act by this mechanism include the tricyclic antidepressants, which act on monamine transporters in general, and the selective serotonin uptake inhibitors (SSRIs) (Lesch K P and Bengel D, CNS Drugs 4(1995), 302-322). A GABA transport inhibitor, tiagabine, has recently been identified as a potential therapy for epilepsy (Lesch K P and Bengel D, CNS Drugs 4(1995), 302-322. Compounds which modulate glycine transporter function would be expected to alter synaptic levels of glycine and thus affect receptor function. In the case of the GlyT-2 transporter, inhibition of transporter function would produce increased activation of strychnine-sensitive glycine receptors. In the spinal cord, activation of these receptors would be expected to reduce transmission of pain-related information, so inhibition of the GlyT-2 transporter could alleviate neuropathic or other pain sensation (e.g. Simpson R K et al, Neurochem. Res. (1996) 21, 1221-1226). In addition, activation of strychnine-sensitive glycine receptors can reduce muscle hyperactivity, which can be related to conditions such as myoclonus, epilepsy and spasticity (e.g. Simpson R K et al, J. Spinal Cord Med. (1996) 19, 215-224). Therefore, inhibition of the glycine transporter could alleviate spasticity or other muscle hyperactivity associated with epilepsy, stroke, head trauma, spinal cord injury, dystonia, multiple sclerosis amyotrophic lateral sclerosis, Huntington's Disease or Parkinson's Disease


REFERENCES:
patent: 5919653 (1999-07-01), Albert et al.
patent: WO 90/06047 (1990-06-01), None
patent: WO 93/10228 (1993-05-01), None
patent: WO 97/45446 (1997-12-01), None
patent: WO 98/07854 (1998-02-01), None
Liu et al. “Cloning and Expression of a Spinal Cord- and Brain-specific Glycine Transporter with Novel Structural Features”, Journal of Biological Chemistry, vol. 268 (30), pp. 22802-22808 (1993).
Ponce et al. “Characterization of the 5′ region of the rat brain glycine transporter GLYT2 gene: Identification of a novel isoform”, Neuroscience Letters, vol. 242, pp. 25-28 (1998).
GenBank Accession No. L21672 (Dec. 31, 1993).
PIR Accession No. A48716 (Jun. 2, 1995).
Verma et al. “Gene therapy—promises, problems and prospects”, Nature 389: 239-242 (1997).
Orkin et al. “Report and recommendations of the panel to assess the NIH investment in research on gene therapy”, issued by the U.S. National Institute of Health (1995).

Affiliated with

Also associated with

Rating

Neurotransmitter transporter SC6 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurotransmitter transporter SC6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotransmitter transporter SC6 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2850177